AstraZeneca PLC (STO:AZN)

Sweden flag Sweden · Delayed Price · Currency is SEK
1,358.00
-18.50 (-1.34%)
Jul 11, 2025, 2:59 PM CET
-16.97%
Market Cap 2.13T
Revenue (ttm) 551.90B
Net Income (ttm) 78.01B
Shares Out n/a
EPS (ttm) 49.88
PE Ratio 27.31
Forward PE 16.21
Dividend 33.75 (2.51%)
Ex-Dividend Date Feb 20, 2025
Volume 106,604
Average Volume 277,696
Open 1,372.00
Previous Close 1,376.50
Day's Range 1,355.00 - 1,372.50
52-Week Range 1,226.00 - 1,799.00
Beta 0.17
RSI 50.62
Earnings Date Jul 29, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Sector Healthcare
Founded 1992
Employees 94,300
Stock Exchange Nasdaq Stockholm
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD Financial Statements

News

Artelo Biosciences Analyst See It As An Emerging Biotech

D. Boral Capital upgraded Artelo Biosciences, Inc. (NASDAQ: ARTL) on Tuesday. The analyst upgraded from Hold to Buy and introduced a price forecast of $20 . Analyst Jason Kolbert wrote, “We continue ...

2 days ago - Benzinga

What's Behind The Recent Rally In IonQ Stock?

IonQ Inc. (NYSE: IONQ) shares climbed above $47.85 Tuesday morning before pulling back. The stock is still up approximately 13.5% over the past month. Here’s a look at what’s driving the recent price...

2 days ago - Benzinga

Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.

7 days ago - Investopedia

AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment

In a high-stakes maneuver that could reshape the oncology landscape, AstraZeneca Plc (NASDAQ: AZN) is reportedly in talks with Summit Therapeutics Inc. (NASDAQ: SMMT) about a partnership worth up to...

7 days ago - Benzinga

Report: Summit in talks for $15 billion partnership with AstraZeneca

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca

7 days ago - CNBC Television

Report: Summit in talks for $15 billion partnership with AstraZeneca

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca

7 days ago - CNBC

Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports

Summit Therapeutics is considering an up to $15 billion partnership with AstraZeneca , Bloomberg News reported on Thursday, citing people familiar with the matter.

7 days ago - Reuters

New London IPOs hit 28-year low amid AstraZeneca exit concerns

More than $100 billion worth of London-listed companies have announced or executed plans to move to New York in recent years.

8 days ago - Fortune

Wise Becomes the Latest UK Giant to Eye a Transatlantic Escape

Wise plans to move its primary listing from London to the US for better capital access, joining AstraZeneca and others in doing so. The post Wise Becomes the Latest UK Giant to Eye a Transatlantic Esc...

8 days ago - Investomania

Price Over Earnings Overview: AstraZeneca

In the current session, AstraZeneca Inc. (NASDAQ: AZN) is trading at $71.17, after a 0.41% decrease. Over the past month, the stock fell by 2.51% , and in the past year, by 7.98% . With performance l...

8 days ago - Benzinga

If AstraZeneca goes to the US it will be a major blow for London and Labour

Move would deprive LSE of its biggest star and could topple a key pillar of the government’s industrial strategy Three years ago Pascal Soriot received the ultimate accolade for turning around AstraZe...

8 days ago - The Guardian

AstraZeneca exit: here's what it really means for the UK

AstraZeneca Plc (LON: AZN) is in focus this morning following reports that its chief executive – Pascal Soriot is considering moving the giant's listing to the US.

8 days ago - Invezz

AstraZeneca Navigates Challenges and Opportunities in 2025

As of July 2, 2025, AstraZeneca, the largest company according to market capitalization of the largest country the United Kingdom, is still a key to the world scenario in the global pharmaceutical mar...

9 days ago - ABC Money

London stock market could weather its biggest blow yet if AstraZeneca exits

AstraZeneca is the most valuable company listed on Londons FTSE 100 index.

9 days ago - CNBC

London’s New Listings Hit 28-Year Low as AstraZeneca Weighs Exit

London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca Plc’s chief executive officer wants to move the company’s listing to the U...

9 days ago - Financial Post

Astra reportedly looks to move its listing across the Atlantic

The Times reports that AstraZeneca, the U.K.'s most valuable public company, is looking to move its listing from London to the U.S. - in a move that could strip the FTSE 100 of a firm that accounts fo...

9 days ago - CNBC

AstraZeneca exit is a frightening prospect for the City and the government

It's a threat that will send a shiver down the spine of Downing Street and shake the City of London to its core..

9 days ago - Sky News

AstraZeneca boss ‘wants to shift stock market listing to US’

Report claims CEO Pascal Soriot talked in private about moving UK’s most valuable listed company and considered shifting its domicile AstraZeneca’s chief executive Pascal Soriot has reportedly said th...

9 days ago - The Guardian

AstraZeneca Shares Rise as CEO Eyes US Stock Market Move

AstraZeneca’s 2.6% share jump follows CEO’s US listing hint, another major blow to London’s stock market pride. The post AstraZeneca Shares Rise as CEO Eyes US Stock Market Move appeared first on Inve...

9 days ago - Investomania